Clinical Trial

The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and efficacy of Apatinib combined with cytokine-induced killer cell (CIK) vs Apatinib alone as the third line therapy for advanced lung adenocarcinoma patients with wild-type EGFR
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2015-07-08.
Status change: Not Yet Recruiting → Active, Not Recruiting 2016-02-04
Trial Details
NCT Number NCT02493582
Lead Sponsor The First People's Hospital of Changzhou
Conditions Adenocarcinoma of Lung
Enrollment 400 participants
Start Date 2015-07
Primary Completion 2030-07 (estimated)
Study Completion 2033-07 (estimated)
Updated on ClinicalTrials.gov 2016-02-05